Gilead Sciences, Inc. $GILD Shares Newly Bought by White Pine Capital LLC

White Pine Capital LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 3,056 shares of the biopharmaceutical company’s stock, valued at approximately $455,000.

A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in Gilead Sciences in the second quarter valued at approximately $15,393,785,000. State Street Corp boosted its stake in shares of Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi boosted its stake in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG bought a new position in shares of Gilead Sciences in the second quarter worth approximately $918,387,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 211,709 shares of company stock worth $35,234,427 over the last quarter. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Jefferies Financial Group set a $196.00 target price on shares of Gilead Sciences in a research note on Wednesday, November 4th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. HSBC lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $184.00 price objective on shares of Gilead Sciences in a report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $171.63.

Read Our Latest Report on Gilead Sciences

Key Headlines Impacting Gilead Sciences

Investors following GILD have been watching these headlines:

  • Positive Sentiment: Gilead signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease post-exposure prevention in 127 primarily low- and lower-middle-income countries. This may broaden access and strengthen Gilead’s profile, though the drug is not yet approved. Reuters article
  • Neutral Sentiment: Barclays raised its price target from $145 to $160 but kept an “equal weight” rating. The higher target is an improvement, although it remains below the stock’s cited recent price, signaling a measured view of further upside. Barclays ratings
  • Negative Sentiment: Zacks Research made mixed earnings revisions: it lowered its Q4 2026 EPS estimate to $1.31 from $2.14 and its FY2026 estimate to a loss of $0.86 per share from a loss of $0.65, while slightly raising its Q1 2028 forecast. The near-term cuts may weigh on sentiment. Zacks Research forecast article

Gilead Sciences Stock Performance

Shares of GILD opened at $167.58 on Tuesday. The company has a 50-day simple moving average of $155.43 and a two-hundred day simple moving average of $141.94. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The firm has a market capitalization of $207.86 billion, a PE ratio of -53.03 and a beta of 0.35. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the prior year, the business earned $2.47 EPS. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.